Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Home
/
update
/
details

Redcliffe Labs Introduces Gut Microbiome and HealthEx Tests to Enhance Preventive Healthcare

NextEdge Admin

20 Sep 2024

2 min 47 sec

Redcliffe Labs has expanded its diagnostic services with the launch of two specialized tests: the Gut Microbiome Test and HealthEx. Available across 220+ cities in India, these tests aim to enhance preventive healthcare by empowering individuals with personalized health insights.

As lifestyle and non-communicable diseases rise across the country, Redcliffe Labs focuses on early detection to help individuals take control of their health. The Gut Microbiome Test, a non-invasive tool, offers a comprehensive analysis of gut health, which is influenced by factors such as diet, genetics, and lifestyle. It provides insights into immune function, hormonal balance, cognitive performance, and metabolic health, addressing issues like obesity, diabetes, and cardiac health. The test also identifies conditions related to auto-immunity, dermatology, and mental health, and includes a 12-week personalized nutrition plan along with expert counseling to support gut health restoration.

The HealthEx test evaluates an individual’s DNA to identify potential health risks associated with lifestyle, diet, and genetics. This advanced blood test offers personalized recommendations for diet, fitness, cardiac health, sleep quality, and cancer risk. Both tests aim to help individuals make informed health decisions and adopt proactive lifestyle changes.

Aditya Kandoi, Founder and CEO of Redcliffe Labs, emphasized the importance of early detection and personalized care in achieving better health outcomes. Dr. Geetanjali Gupta, Director of Technical Operations & Quality Assurance, highlighted how these tests help monitor vital health markers, enabling healthcare providers to optimize treatment plans.

Both tests are available through Redcliffe Labs’ app, website, and collection centers, offering a seamless experience. The Gut Microbiome Test is for individuals aged six and above, while HealthEx is available for those over five years old, reinforcing Redcliffe Labs’ commitment to preventive healthcare.